An M-spike (monoclonal spike) is an abnormal band of protein that shows up on a blood test called serum protein electrophoresis, or SPEP. It signals that one group of cells in your immune system is producing large amounts of a single, identical antibody. In most cases, an M-spike points to a common, noncancerous condition called MGUS, but it can also be an early sign of blood cancers like multiple myeloma.
How the Test Works
Serum protein electrophoresis separates the proteins in your blood by size and electrical charge, spreading them across a gel strip. In a healthy sample, the proteins form a smooth, gently rolling pattern. When one clone of immune cells overproduces a single antibody, that protein piles up in one spot on the strip, creating a sharp, narrow peak. That peak is the M-spike. It’s sometimes called a paraprotein or monoclonal protein.
The M-spike is measured in grams per deciliter (g/dL). A normal result shows no monoclonal peak at all. Any detectable spike triggers further investigation, and the size of the spike helps determine what it means.
Why Your Body Produces a Monoclonal Protein
Your immune system normally makes millions of different antibodies, each produced by a different group of plasma cells in your bone marrow. When one group of plasma cells begins multiplying abnormally, it churns out a flood of one specific antibody. That flood is what the SPEP picks up as an M-spike.
The most common reason this happens is a condition called monoclonal gammopathy of undetermined significance (MGUS). MGUS is not cancer. It causes no symptoms and requires no treatment, though it does need monitoring because a small percentage of people with MGUS eventually develop a blood cancer. Less commonly, an M-spike can reflect multiple myeloma, a related precancer called smoldering myeloma, or a lymphoma variant called Waldenström macroglobulinemia.
Not every M-spike is permanent. Infections, including hepatitis B, hepatitis C, HIV, and certain bacterial infections, can trigger a temporary monoclonal protein that disappears once the infection resolves. Autoimmune diseases like lupus and rheumatoid arthritis have also been linked to transient M-spikes.
What the Size of the Spike Means
The M-spike level is one of the key numbers doctors use to distinguish between conditions. The thresholds work like this:
- Less than 3 g/dL with no symptoms: Typically classified as MGUS, provided fewer than 10% of bone marrow cells are abnormal plasma cells and there’s no organ damage.
- 3 g/dL or higher, or 10% or more bone marrow plasma cells, but still no symptoms: Classified as smoldering multiple myeloma. This is a step closer to active disease but still requires no immediate treatment.
- Any M-spike level with organ damage: When the abnormal protein or the plasma cells behind it cause specific problems (high calcium, kidney failure, anemia, or bone lesions), the diagnosis shifts to active multiple myeloma regardless of how large the spike is.
These organ-damage markers are sometimes grouped under the acronym CRAB: Calcium elevation, Renal (kidney) failure, Anemia, and Bone lesions. Doctors check for all four when evaluating an M-spike.
Follow-Up Tests After an M-Spike
Finding an M-spike on SPEP is just the starting point. The next step is usually immunofixation electrophoresis (IFE), which identifies the exact type of antibody being overproduced. Antibodies are made of heavy chains and light chains, and IFE pinpoints which combination is involved, such as IgG kappa or IgA lambda. This matters because different antibody types carry different risk profiles. An IgM-type M-spike, for instance, may point toward Waldenström macroglobulinemia rather than myeloma.
Doctors also typically order a serum free light chain assay. This measures two types of antibody fragments (kappa and lambda light chains) floating freely in your blood and calculates their ratio. A normal kappa-to-lambda ratio falls between 0.26 and 1.65. The further that ratio drifts from normal, the more concerning the finding. A ratio of 100 or higher (or 0.01 or lower) in someone with smoldering myeloma is associated with a significantly increased risk of progressing to active myeloma within two years.
Depending on these initial results, additional testing might include a bone marrow biopsy to count the percentage of abnormal plasma cells, imaging to check for bone damage, and blood work to assess kidney function, calcium levels, and red blood cell counts.
MGUS: The Most Common Explanation
For most people, an M-spike turns out to be MGUS. It becomes increasingly common with age and is found in roughly 3% to 4% of the general population over 50. MGUS causes no symptoms on its own, and most people with it never develop a related cancer. The overall risk of MGUS progressing to myeloma or a related disease is about 1% per year.
Because that risk is ongoing, MGUS requires regular monitoring. This usually means repeat blood work every 6 to 12 months to track whether the M-spike is growing. A stable or slowly rising spike is reassuring. A spike that climbs toward 3 g/dL, or new symptoms like unexplained bone pain, fatigue, or kidney problems, would prompt more urgent evaluation.
When an M-Spike Signals Something More Serious
Smoldering myeloma sits between MGUS and active myeloma. People with this diagnosis have a larger protein burden (M-spike of 3 g/dL or more, or at least 10% plasma cells in the bone marrow) but no organ damage yet. The risk of progressing to active myeloma is roughly 10% per year in the first five years, then gradually decreases. Monitoring is more frequent and intensive than for MGUS.
Active multiple myeloma is diagnosed when the abnormal plasma cells start causing measurable harm: bones weakening or developing holes, kidneys losing function, calcium levels rising in the blood, or red blood cell counts dropping. At that point, treatment begins. Importantly, about 21% of people who progress from MGUS to active myeloma skip the smoldering stage entirely, meaning their M-spike never reaches 3 g/dL before organ damage appears. This is one reason regular monitoring matters even when the spike is small.
Waldenström macroglobulinemia is a separate condition where the monoclonal protein is specifically an IgM antibody, produced by a type of lymphoma cell rather than a pure plasma cell. It has its own diagnostic workup and treatment approach, distinct from myeloma.
What to Expect After Your Result
If your blood test showed an M-spike for the first time, the practical next steps are straightforward. Your doctor will order immunofixation and free light chain testing to characterize the protein, and likely check your blood counts, kidney function, and calcium. If everything else looks normal and the spike is small, you’re almost certainly looking at MGUS and a plan of regular blood draws to keep an eye on it.
The M-spike number itself becomes a personal baseline. Future tests will compare against it to watch for changes. A stable number over months and years is the most common outcome and the most reassuring one.